Allogene Therapeutics Inc. (ALLO)
NASDAQ (NGS) NASDAQ (NGS) Primary 
Allogene Therapeutics, Inc. (ALLO) Presents at Citi's 2026 Virtual Oncology Leadership Summit Transcript
Allogene Therapeutics, Inc. (ALLO) Presents at Citi's 2026 Virtual Oncology Leadership Summit Transcript
Are Medical Stocks Lagging Allogene Therapeutics (ALLO) This Year?
Here is how Allogene Therapeutics (ALLO) and McKesson (MCK) have performed compared to their sector so far this year.
Rapid Innovation is Reshaping Oncology: Stocks in Focus
Rapid advances in immunotherapy, targeted drugs & artificial intelligence-driven research are reshaping oncology, spotlighting select cancer stocks to watch now.
Is Allogene Therapeutics (ALLO) Stock Outpacing Its Medical Peers This Year?
Here is how Allogene Therapeutics (ALLO) and Alzamend Neuro, Inc. (ALZN) have performed compared to their sector so far this year.
Are Medical Stocks Lagging Allogene Therapeutics (ALLO) This Year?
Here is how Allogene Therapeutics (ALLO) and AN2 Therapeutics, Inc. (ANTX) have performed compared to their sector so far this year.
Allogene Posts Narrower-Than-Expected Loss in Q3, Nil Sales
ALLO's Q3 loss narrows to 19 cents per share, beating estimates, as R&D and G&A costs decline despite no product sales.
Allogene Therapeutics, Inc. (ALLO) Q3 2025 Earnings Call Transcript
Allogene Therapeutics, Inc. ( ALLO ) Q3 2025 Earnings Call November 6, 2025 5:00 PM EST Company Participants Christine Cassiano - Executive VP, Chief Corporate Affairs & Brand Strategy Officer David Chang - Co-Founder, President, CEO & Director Zachary Roberts - Executive VP of Research & Development and Chief Medical Officer Geoffrey Parker - Executive VP & CFO Conference Call Participants Salveen Richter - Goldman Sachs Group, Inc., Research Division Tyler Van Buren - TD Cowen, Research Division Jack Allen - Robert W. Baird & Co. Incorporated, Research Division Samantha Corwin - William Blair & Company L.L.C.
Allogene Therapeutics, Inc. (ALLO) Presents at Citi's SMID Call Series 2025 Transcript
Allogene Therapeutics, Inc. (NASDAQ:ALLO ) Citi's SMID Call Series 2025 October 2, 2025 1:00 PM EDT Company Participants Zachary Roberts - Executive VP of Research & Development and Chief Medical Officer Conference Call Participants Samantha Semenkow - Citigroup Inc., Research Division Presentation Samantha Semenkow Citigroup Inc., Research Division Good afternoon, and thank you for joining. I'm Sam Semenkow, one of the senior biotech analysts here at Citi, and it's my pleasure to be hosting Allogene's Executive Vice President and CMO, Zach Roberts, as a part of Citi's SMID Biotech C-suite virtual fireside chat series.
Allogene Therapeutics: Important Catalysts Guided For Early 2026
I maintain a 'Buy' rating on Allogene Therapeutics, as their diverse allogeneic cell therapy pipeline shows encouraging early data and pivotal trials are progressing. ALLO's financial position remains solid, with over $300 million in liquidity, sufficient to reach key data catalysts through 2027 despite brisk cash burn. The upcoming ALPHA3 futility analysis in 1H 2026 is a critical catalyst; positive MRD data could significantly revalue the stock from current depressed levels.
Allogene's Q2 Loss Narrower Than Expected, Pipeline in Focus
ALLO posts a narrower second-quarter 2025 loss. The company advances multiple CAR T programs targeting cancer and autoimmune diseases.
Allogene Therapeutics, Inc. (ALLO) Q2 2025 Earnings Call Transcript
Allogene Therapeutics, Inc. (NASDAQ:ALLO ) Q2 2025 Earnings Conference Call August 13, 2025 5:00 PM ET Company Participants Christine Cassiano - Executive VP, Chief Corporate Affairs & Brand Strategy Officer David D. Chang - Co-Founder, President, CEO & Director Geoffrey M.
Betting Big on Cancer: 3 Oncology Stocks Set to Surge in 2025
J&J, Novartis and Allogene Therapeutics are making bold oncology moves as demand surges for next-generation cancer therapies.
